The rapid expansion of peptide therapeutics manufacturing, the accelerating demand for the RNA therapeutics CDMO market, and the growing reliance on GMP peptide synthesis services are reshaping the global biopharmaceutical manufacturing ecosystem. These advancements are central to the development of next-generation biologics and nucleic acid-based therapies, enabling faster, scalable, and high-quality production of complex molecules.

The Peptide and Oligonucleotide CDMO Market was valued at USD 3.5 billion in 2024 and is projected to reach USD 4 billion in 2025. Driven by strong demand for peptide and nucleic acid-based therapeutics, the market is expected to grow at a CAGR of 15.1% from 2025 to 2034, reaching approximately USD 14.2 billion by 2034.

Peptide Therapeutics Manufacturing Enabling Advanced Drug Development

Peptide therapeutics manufacturing has become a critical component of modern drug development due to the rising success of peptide-based medicines in treating metabolic disorders, cancer, cardiovascular diseases, and infectious conditions.

Peptides offer several advantages:

• High target specificity
• Low toxicity compared to small molecules
• Ability to mimic natural biological processes
• Broad therapeutic applications

However, peptide manufacturing is highly complex due to challenges in sequence length, purification, aggregation control, and stability. As a result, pharmaceutical companies increasingly outsource production to specialized CDMOs with advanced synthesis capabilities.

Modern manufacturing approaches include solid-phase peptide synthesis (SPPS), liquid-phase synthesis, and hybrid technologies that improve yield, purity, and scalability. This growing complexity continues to drive demand within the Peptide and Oligonucleotide CDMO Market, particularly for high-quality GMP-compliant production systems.

RNA Therapeutics CDMO Market Expanding Through Nucleic Acid Innovation

The RNA therapeutics CDMO market is experiencing rapid growth due to the increasing adoption of RNA-based modalities such as mRNA vaccines, siRNA therapies, and antisense oligonucleotides (ASOs). These therapies are revolutionizing the treatment landscape by targeting disease mechanisms at the genetic level.

Key RNA therapeutic categories include:

• mRNA-based vaccines and protein replacement therapies
• siRNA for gene silencing applications
• ASOs for splicing and gene regulation
• RNA aptamers for targeted binding

The success of mRNA vaccines during global health crises has significantly accelerated investment in RNA platforms. However, RNA molecules are highly sensitive and require advanced formulation, stabilization, and delivery systems.

CDMOs play a crucial role by offering:

• RNA synthesis and modification
• Lipid nanoparticle (LNP) formulation
• Analytical and stability testing
• GMP-scale manufacturing and fill-finish services

These capabilities are essential for translating RNA research into commercial therapies and are a key growth driver for the broader Peptide and Oligonucleotide CDMO Market.

GMP Peptide Synthesis Services Ensuring Quality and Compliance

GMP peptide synthesis services are essential for ensuring that peptide-based therapeutics meet strict regulatory and quality standards required for clinical and commercial use.

Good Manufacturing Practice (GMP) ensures:

• Batch-to-batch consistency
• High purity and impurity control
• Regulatory compliance (FDA, EMA, ICH)
• Safe and reproducible production

GMP peptide synthesis includes multiple stages such as:

• Process development and optimization
• Scalable peptide assembly
• Purification using HPLC techniques
• Lyophilization and formulation
• Quality control and stability testing

As peptides move from research to clinical applications, demand for GMP-compliant services increases significantly. CDMOs offering integrated GMP solutions are becoming indispensable partners for pharmaceutical and biotechnology companies seeking to accelerate drug development timelines.

Market Growth Drivers and Industry Dynamics

The Peptide and Oligonucleotide CDMO Market is expanding rapidly due to several key drivers:

• Increasing pipeline of peptide and RNA-based drugs
• Rising outsourcing of drug development and manufacturing
• Growth in precision medicine and targeted therapies
• Advances in synthesis and purification technologies
• Expanding biologics and nucleic acid therapeutics sector

Additionally, the complexity of manufacturing peptides and oligonucleotides encourages pharmaceutical companies to rely heavily on CDMOs for cost efficiency and technical expertise.

Segment Insights

By Product Type

Peptides account for a dominant share due to their widespread use in metabolic and oncology therapies, while oligonucleotides and RNA-based therapeutics are rapidly growing segments driven by gene therapy innovations.

By Service Type

Contract manufacturing holds a major share, as companies increasingly outsource large-scale production, while contract development services are expanding due to growing early-stage drug pipelines.

By End User

Pharmaceutical and biotechnology companies are the primary end users, followed by research institutes engaged in early-stage discovery and clinical development.

Discover the Complete Report Here:

https://www.polarismarketresearch.com/industry-analysis/peptide-and-oligonucleotide-cdmo-market

Some of the major players operating in the global peptide and oligonucleotide CDMO market include:

• Aurigene Pharmaceutical Services Ltd.
• Bachem Group
• CordenPharma
• Creative Peptides
• Curia Global, Inc.
• EUROAPI
• Genscript Biotech Corporation
• Lonza Group
• Merck KGaA
• PolyPeptide Group
• Senn Chemicals AG
• STA Pharmaceutical Co. Ltd.
• Sylentis, S.A.
• Thermo Fisher Scientific Inc.
• Wuxi AppTec

Regional Analysis

North America

North America leads the Peptide and Oligonucleotide CDMO Market due to strong biotech infrastructure, high R&D investment, and the presence of leading CDMO players.

Europe

Europe maintains strong growth supported by regulatory expertise, advanced pharmaceutical manufacturing capabilities, and rising biologics development.

Asia Pacific

Asia Pacific is expected to witness the fastest growth due to lower manufacturing costs, expanding CDMO capacity, and increasing global outsourcing trends.

Latin America and Middle East & Africa

These regions are gradually expanding pharmaceutical manufacturing capabilities and improving access to advanced biologic therapies.

Future Outlook

The future of peptide therapeutics manufacturing, the RNA therapeutics CDMO market, and GMP peptide synthesis services will be shaped by technological innovation and increased industrial collaboration.

Key emerging trends include:

• AI-driven process optimization and molecular design
• Continuous and automated peptide synthesis platforms
• Advanced RNA stabilization and delivery systems
• Expansion of end-to-end integrated CDMO services
• Sustainable and green chemistry manufacturing approaches

As the demand for precision medicine continues to rise, the Peptide and Oligonucleotide CDMO Market is expected to maintain strong and sustained growth. CDMOs will play a central role in enabling faster development, scalable production, and global commercialization of next-generation peptide and RNA therapeutics.

More Trending Latest Reports By Polaris Market Research:

Atopic Dermatitis Market

Mammalian Polyclonal IgG Antibody Market

Injection Pen Market

U.S. Patient Temperature Management Market

Scientific Data Management System Market

Ear Infection Treatment Market

Autoinjectors Market

Direct Oral Anticoagulants (DOACs) Device Market